Clinical Failures of Linezolid and Implications for the Clinical Microbiology Laboratory

摘要

Linezolid is the first in a new class of antimicrobials, theoxazolidinones. This antimicrobial is approved to treatgram-positive infections caused by vancomycin-resistantenterococci (VRE) and methicillin-resistant Staphylococcusaureus (MRSA) (1). Newer antibiotics have provided clini-cians greater treatment options; however, ongoing experienceshow s limitations in their use. We report two patients withinfections caused by linezolid-resistant and possible linezolid-nonsusceptible bacteria and provide commentary on theincreasing bacterial resistance to linezolid and quinupristin/dalfopristin, as well as the appropriate use of these and futureantibiotics